<DOC>
	<DOC>NCT01949103</DOC>
	<brief_summary>TD-1607, administered intravenously as multiple ascending doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.</brief_summary>
	<brief_title>TD-1607 MAD Study in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Subject is a healthy nonsmoking male or a female (of nonchildbearing potential) and 18 to 55 years old, inclusive, at Screening. Subject has a body mass index (BMI) of 19 to 30 kg/m2, inclusive, and weighs at least 50 kg. Subject has no clinically significant abnormalities in the results of laboratory evaluations at Screening and Day 1. Subject has evidence or history of clinically significant, relevant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (except for untreated, asymptomatic seasonal allergies at time of dosing). Subject has a history of allergies or hypersensitivities to glycopeptide (e.g., vancomycin) or betalactam (e.g., penicillin or cephalosporin) antibiotics. Subject has participated in another clinical trial of an investigational drug (or medical device) within 60 days (or 5 halflives, whichever is longer) prior to Screening or is currently participating in another trial of an investigational drug (or medical device). Subject has previously participated in a trial for TD1607.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gram-positive</keyword>
</DOC>